Business Context and Reporting Period
The provided filing is Aadi Bioscience, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2023, not Whitehawk Therapeutics, Inc. Aadi is a commercial-stage biopharmaceutical company developing precision cancer therapies targeting mTOR-pathway alterations. Its lead product, FYARRO, was FDA-approved for advanced malignant PEComa in November 2021 and launched in the United States in February 2022.
Financial Performance and Position
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Net product sales | $6.0 million, versus $4.2 million in 2022 | $18.0 million, versus $10.0 million in 2022 |
| Operating expenses | $23.8 million, versus $19.3 million | $72.2 million, versus $57.2 million |
| Loss from operations | $(17.8) million, versus $(15.0) million | $(54.2) million, versus $(47.2) million |
| Net loss | $(16.3) million, versus $(14.5) million | $(49.5) million, versus $(46.6) million |
| Net loss per share | $(0.60), versus $(0.68) | $(1.84), versus $(2.21) |
Calculated operating margins were approximately negative 300% for both the quarter and nine-month period. Net margins were approximately negative 274% for both periods. Higher product revenue did not offset continued research, commercialization and corporate costs.
- Interest income was $1.6 million in the quarter and $4.9 million for the nine months, compared with $0.6 million and $0.8 million, respectively, in the prior-year periods.
- Cash used in operating activities was $50.0 million for the nine months, compared with $38.3 million in 2022.
- Investing activities provided $79.6 million, primarily because $133.3 million of short-term investments matured, partly offset by $50.5 million of purchases and $3.2 million of capital expenditures.
- Financing activities provided $0.2 million; the prior-year period benefited from $72.5 million of gross proceeds from the 2022 PIPE financing.
- Cash, cash equivalents and short-term investments totaled $119.3 million at September 30, 2023, including $68.8 million of cash and cash equivalents and $50.5 million of short-term investments.
- Total liabilities were $21.5 million. The principal financing-related obligation was a $5.8 million amount due to BMS, payable August 26, 2024, plus accrued interest. Operating lease liabilities totaled $1.4 million.
- Accumulated deficit was $252.7 million. No cash dividends have been declared or paid.
Material Changes Versus the Prior Comparable Period
- Quarterly revenue increased 40% and nine-month revenue increased 80%, reflecting continued FYARRO commercialization.
- Quarterly SG&A increased $1.3 million to $11.2 million, while nine-month SG&A increased $5.1 million to $34.2 million. The increases were attributed primarily to legal expenses, marketing, personnel and commercialization activities.
- Quarterly R&D expense increased $3.1 million to $11.9 million, and nine-month R&D expense increased $12.9 million to $36.2 million, driven by personnel, PRECISION1 clinical development and manufacturing costs.
- The prior-year nine-month period included a $3.7 million impairment of an acquired contract intangible asset related to the terminated Gossamer license; no comparable charge was recorded in 2023.
- Net loss increased by $1.8 million for the quarter and $2.9 million for the nine months despite higher revenue, as operating expenses grew faster than sales.
- Cash and cash equivalents increased from $39.0 million at December 31, 2022 to $68.8 million, while short-term investments declined from $133.5 million to $50.5 million, largely reflecting investment maturities and reallocation into cash.
Guidance, Outlook, Commentary, Risks and Unusual Items
- Management stated that existing cash, cash equivalents and short-term investments are expected to fund planned operations into 2025. The liquidity note separately states that resources are sufficient for at least twelve months from the filing date.
- Aadi expects continued operating losses and significant expenses as it commercializes FYARRO and funds clinical development in PEComa, TSC1/TSC2-altered tumors, endometrial cancer and neuroendocrine tumors.
- An interim analysis of the PRECISION1 trial, covering approximately 40 patients, was planned for mid-December 2023.
- Aadi announced a leadership transition: David J. Lennon became President and CEO effective October 2, 2023, replacing interim CEO Scott Giacobello, who remained CFO.
- Aadi adopted a 2023 Inducement Equity Incentive Plan reserving 600,000 common shares for new-employee grants. Stock-based compensation was $3.0 million in the quarter and $8.8 million for the nine months.
- The company is dependent on a single third-party manufacturer, Fresenius Kabi, for FYARRO drug product and had $3.6 million of non-cancellable inventory purchase commitments due in 2023 under the Fresenius agreement.
- EOC terminated its regional FYARRO license in June 2022 and has an ongoing arbitration proceeding seeking monetary damages. Aadi cannot estimate the potential loss and has accrued no liability.
- Aadi owes BMS the $5.8 million balloon payment due in August 2024, plus interest, and pays royalties on FYARRO net sales.
- Two customers represented 56% and 44% of quarterly revenue and 54% and 46% of nine-month revenue. Two customers represented all accounts receivable at September 30, 2023.
- Key risks include dependence on a single commercial product, limited operating history, continued losses and potential future dilution, regulatory and clinical-trial uncertainty, reimbursement and pricing pressure, supply-chain dependence, intellectual-property and licensing risks, and the ongoing EOC arbitration.
- Management concluded that disclosure controls and procedures were effective as of September 30, 2023, with no material changes in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Aadi Bioscience, Inc. and trades under Nasdaq symbol AADI, despite the request identifying Whitehawk Therapeutics, Inc.
- Reconcile FYARRO revenue growth with customer concentration, gross-to-net allowances and accounts-receivable collections.
- Assess whether the stated cash runway into 2025 remains adequate after operating cash burn, clinical expansion, manufacturing commitments and the August 2024 BMS payment.
- Monitor PRECISION1 and the newer endometrial cancer and neuroendocrine tumor programs for enrollment, efficacy, safety and regulatory progress.
- Track the EOC arbitration, including any estimate of potential damages or settlement exposure.
- Review the Fresenius Kabi agreement, minimum purchase obligations and availability of alternative FYARRO suppliers.
- Consider potential dilution from outstanding options, warrants, employee plans and the unused $75.0 million at-the-market facility.